HOOKIPA Pharma Inc. financial data

Symbol
HOOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Fifth Avenue, 72 Nd Floor, Suite 7240, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 376 % +5.25%
Debt-to-equity 53.9 % -28.2%
Return On Equity -49.3 % +29.8%
Return On Assets -32 % +20.2%
Operating Margin -122 % +68.9%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 71.7M USD -13.2%
Weighted Average Number of Shares Outstanding, Basic 12.5M shares +13.6%
Weighted Average Number of Shares Outstanding, Diluted 12.5M shares +13.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 50M USD +143%
Research and Development Expense 76.6M USD -7.5%
General and Administrative Expense 19.1M USD +5.66%
Costs and Expenses 111M USD +9.86%
Operating Income (Loss) -60.9M USD +24.3%
Nonoperating Income (Expense) 17.7M USD +50.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.2M USD +37.1%
Income Tax Expense (Benefit) 163K USD -62.4%
Net Income (Loss) Attributable to Parent -43.4M USD +37.2%
Earnings Per Share, Basic 0.81 USD/shares +36.4%
Earnings Per Share, Diluted 0.81 USD/shares +36.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.8M USD -44.5%
Accounts Receivable, after Allowance for Credit Loss, Current 324K USD -52%
Assets, Current 93.2M USD -33.2%
Property, Plant and Equipment, Net 6.86M USD -66%
Operating Lease, Right-of-Use Asset 2.86M USD 0%
Other Assets, Noncurrent 660K USD -39.6%
Assets 110M USD -33.1%
Accounts Payable, Current 8.96M USD +0.29%
Contract with Customer, Liability, Current 4.65M USD -75.6%
Liabilities, Current 28.6M USD -29.6%
Contract with Customer, Liability, Noncurrent 2.62M USD -91.4%
Operating Lease, Liability, Noncurrent 1.62M USD +21.7%
Other Liabilities, Noncurrent 6.06M USD +81.8%
Liabilities 37.9M USD -45%
Accumulated Other Comprehensive Income (Loss), Net of Tax -8.58M USD -42.4%
Retained Earnings (Accumulated Deficit) -388M USD -12.6%
Stockholders' Equity Attributable to Parent 71.8M USD -24.5%
Liabilities and Equity 110M USD -33.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.2M USD -748%
Net Cash Provided by (Used in) Financing Activities -135K USD +81.6%
Net Cash Provided by (Used in) Investing Activities -116K USD +57.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.86M USD -105%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60M USD -44.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1K USD
Deferred Tax Assets, Valuation Allowance 89.3M USD +35.8%
Deferred Tax Assets, Gross 94.4M USD +34.5%
Operating Lease, Liability 2.8M USD 0%
Payments to Acquire Property, Plant, and Equipment 116K USD -57.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.9M USD +31.9%
Lessee, Operating Lease, Liability, to be Paid 5.85M USD +44.1%
Property, Plant and Equipment, Gross 17.3M USD -40.6%
Operating Lease, Liability, Current 1.21M USD -19.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.63M USD +23.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.66M USD +5.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +250%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 412K USD +565%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.35M USD +15.1%
Deferred Tax Assets, Operating Loss Carryforwards 87.4M USD +32.1%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.21M USD
Additional Paid in Capital 468M USD +5.09%
Depreciation, Depletion and Amortization 640K USD -30.5%
Deferred Tax Assets, Net of Valuation Allowance 5.05M USD +15.3%
Share-based Payment Arrangement, Expense 1.57M USD +63.6%
Interest Expense 197K USD -65.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%